Keyphrases
Computed Tomography
100%
Response to Treatment
100%
Colorectal Liver Metastases
100%
Bevacizumab
100%
Positron Emission Tomography-computed Tomography (PET-CT)
100%
Irinotecan
100%
Response Evaluation
100%
Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
60%
Fluorodeoxyglucose Positron Emission Tomography/computed Tomography
60%
18F-fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET)
60%
Liver Metastasis
40%
Neoadjuvant
40%
Complete Response
40%
Retrospective Survey
20%
Consecutive Patients
20%
Positron Emission Tomography
20%
Disease Progression
20%
Necrosis
20%
Surrogate Marker
20%
Treatment Response
20%
Pathologic
20%
Liver Lesions
20%
Response Evaluation Criteria in Solid Tumors (RECIST)
20%
Metabolic Imaging
20%
Computed Tomography Findings
20%
Pathological Response
20%
4-cycle
20%
Patients with Colorectal Cancer
20%
Anatomic Localization
20%
Stable Disease
20%
Contrast-enhanced Computed Tomography
20%
Non-enhanced Computed Tomography
20%
Tumor Viability
20%
Combined Modality
20%
Metastasectomy
20%
18F-fluorodeoxyglucose Uptake
20%
Size Criteria
20%
Medicine and Dentistry
Computer Assisted Tomography
100%
Colorectal Cancer
100%
Liver Metastasis
100%
Positron Emission Tomography-Computed Tomography
100%
Bevacizumab
100%
Irinotecan
100%
Positron Emission Tomography
66%
Fluorodeoxyglucose
66%
Fluorodeoxyglucose F 18
44%
Disease
22%
Biopsy
11%
Low Drug Dose
11%
Neoplasm
11%
Necrosis
11%
Disease Marker
11%
Liver Injury
11%
Treatment Response
11%
Metastasectomy
11%
Immunology and Microbiology
Computer Assisted Tomography
100%
Positron Emission Tomography-Computed Tomography
100%
Bevacizumab
100%
Irinotecan
100%
Positron Emission Tomography
66%
Low Drug Dose
11%